# Bunge Global SA (BG) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BG/thesis · /stocks/BG/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: BG
step: 04
title: Financial Quality (Snapshot + Adversarial Sweep)
date: 2026-05-28
---

### Step 04 — Financial Quality

#### Key Findings

- **Earnings quality is structurally low** — net income margins of 0.85-7.85% over CY2021-CY2025 with high cycle volatility; FY2025 reported $816M net income vs $2,243M in CY2023 [S1]. The headline EPS is heavily distorted by mark-to-market gains/losses on the trading book, FX, and Viterra purchase accounting.
- **Adjusted EPS is the primary external metric** — Adj EPS strips out non-cash adjustments (commodity hedge mark-to-market, integration charges, certain divestiture gains/losses). CY2025 adj EPS $7.57 vs GAAP $4.91 = 35% difference [S2]. This wedge is structurally large because of the trading book.
- **Cash conversion is poor in the short run but normalizes over the cycle** — CY2025 OCF $844M vs net income $816M (104% conversion looks OK in isolation, but heavy working-capital build offset trading gains); CY2024 OCF $1,900M vs NI $1,137M (168% — normal); CY2022 OCF NEGATIVE $5.5B vs NI $1.6B (negative working-capital absorption during commodity-price spike) [S1].
- **Adversarial sweep finds NO material short reports, NO active SEC enforcement actions, NO material legal/regulatory overhangs.** Bunge has historically been free from accounting-fraud allegations, unlike Glencore (its largest shareholder, with FCPA history). Bunge had a $112M settlement with the DOJ in 2013 for accounting issues at Argentine subsidiary but no recurrence since.
- **Net read: NEUTRAL.** Quality is cycle-typical for the agribusiness oligopoly — neither best-in-class (like the franchise-business comps) nor problematic. The Adj EPS wedge is large but understood by analysts and consistent across peers (ADM has a similar adjustment pattern).

#### Implications for Thesis and Valuation

- Use Adj EPS, not GAAP EPS, for forward valuation (consistent with how the Street prices the stock).
- Discount the trading-book P&L line in forward modeling — treat as zero-NPV mean-reverting, with quarterly variance built into the equity-cost-of-capital.
- The $14.3B net debt post-Viterra is the single largest balance-sheet risk; rating-agency response to be monitored.
- Working-capital cycle (especially South American harvest timing) creates seasonal OCF swings that are normal but real.

#### Objective

Assess earnings quality, accounting conservatism, cash conversion, balance-sheet integrity, and run an adversarial research sweep for short reports, lawsuits, SEC investigations, and other reputational/governance overhangs.

#### Narrative Analysis

##### Earnings quality — GAAP vs Adjusted

Bunge's GAAP earnings include several material items the Street strips out:
- **Mark-to-market on hedge book** — commodity derivatives held for risk-management purposes generate non-cash gains/losses that don't reflect underlying margin
- **FX translation** — large Brazilian, Argentine, EU footprint generates non-cash FX volatility
- **Integration / restructuring charges** — Viterra-related in 2025-2026
- **Bargain purchase / goodwill items**

CY2025 reconciliation:
- GAAP net income: $816M / GAAP diluted EPS: $4.91 [S1]
- Adj net income: ~$1.46B / Adj EPS: $7.57 [S2]
- Wedge: ~$643M ($2.66 per share) of non-cash / non-operating items added back

Historical adj-vs-GAAP wedges (per StockAnalysis-derived back-calcs):
- CY2024: GAAP $7.99 vs adj $9.19 (15% wedge)
- CY2023: GAAP $14.87 vs adj n/d
- CY2025: GAAP $4.91 vs adj $7.57 (54% wedge) — outsized because of Viterra purchase accounting

This pattern is typical of the agribusiness oligopoly. ADM, Wilmar, and LDC all show similar reconciliations. **For valuation, use Adj EPS consistently.**

##### Cash conversion analysis

OCF vs Net Income over the cycle:

| Year | NI ($M) | OCF ($M) | OCF/NI | Working Capital Δ | Note |
|------|---------|----------|--------|-------------------|------|
| CY2021 | 2,078 | -2,894 | NEGATIVE | -$1,156 | Commodity-price ramp absorbed cash |
| CY2022 | 1,610 | -5,549 | NEGATIVE | -$342 (but inventory + AR build heavy) | Same dynamic, peak commodity prices |
| CY2023 | 2,243 | 3,308 | 1.47x | +$897 | Working-capital release |
| CY2024 | 1,137 | 1,900 | 1.67x | -$463 | Normal cycle |
| CY2025 | 816 | 844 | 1.03x | -$503 + Viterra add | Cycle + integration |

[S1][S2]

**The OCF series is dominated by working-capital swings tied to commodity prices**, not earnings quality. When commodity prices spike (2021-2022), inventory and AR balloon → OCF turns deeply negative even as NI is positive. When prices fall, the unwind shows up as OCF release. This is structurally correct given BG's flow-business nature, but it makes any single-year OCF measurement misleading. **Use multi-year OCF averages, not annual snapshots, for cash quality assessment.**

##### Balance sheet integrity

Post-Viterra (Dec 31, 2025):
- Total assets: $44.5B (vs $24.9B pre-merger)
- Net debt: $14.3B (vs $3.8B pre-merger)
- Equity: $17.4B (vs $10.9B pre-merger)
- Net debt / equity: 0.82 (manageable, but materially elevated)
- Goodwill + intangibles: $3.4B (modest; not a write-down risk)
[S2]

The doubling of assets reflects Viterra consolidation; the elevated leverage is the integration period's main rating-agency variable. S&P / Moody's actions are a monitor (likely BBB / Baa2 range; downgrade risk if deleveraging slips).

##### Adversarial Research Sweep

Methodology: searched for short-report distribution (Muddy Waters, Hindenburg, Citron, Quintessential, Wolfpack, etc.), SEC enforcement actions, class-action litigation, and FCPA/anti-corruption matters involving Bunge.

| Type | Finding | Status |
|------|---------|--------|
| Active short reports | None publicly distributed against BG (current cycle) | Clear |
| Historical short reports | None notable in the past decade | Clear |
| SEC enforcement actions | None current | Clear |
| Historical SEC matter | 2013 — Bunge resolved DOJ/SEC investigation of Argentine subsidiary (Bunge Argentina) tax-fraud allegations with $112M settlement | Resolved >12 years ago; no recurrence |
| FCPA matters | None against Bunge | Clear |
| Recent class actions | None material | Clear |
| Major regulatory fines | Routine commodity-trading regulatory matters; nothing material | Clear |
| EUDR (EU Deforestation Regulation) compliance | Bunge has invested in traceability; recent reports show on-track compliance for 2025 effective date | Clear / on-track |
| ESG controversies | Brazilian Cerrado biome soy sourcing has drawn NGO/Greenpeace criticism over the years; Bunge has issued no-deforestation commitments and traceability investments | Ongoing reputation matter — not a financial risk |

**Glencore overhang note:** Bunge's largest shareholder (~15% post-Viterra) is Glencore plc, which has a documented history of FCPA / bribery / regulatory issues across its mining + trading businesses. As far as I can determine, none of this exposure transfers to Bunge directly (the FCPA matters were settled by Glencore plc; no co-defendant designation for Viterra or Bunge in those actions). But Glencore's reputational/governance profile is something a long-only investor should be aware of, even if it has no direct contagion to BG.

##### Key financial-quality flags

1. **Goodwill / intangibles low** — only $3.4B combined vs $44.5B assets — minimal impairment risk
2. **No debt covenant disclosure suggests material headroom; new $XXBn Viterra-funding facility was syndicated 2025
3. **No going-concern language** ever issued
4. **Audit firm — to confirm from latest 10-K** (likely Deloitte or EY, no recent auditor change controversy)
5. **Restatements** — none material in past 5 years

#### Evidence and Sources

- Annual GAAP series [S1]; Adjusted reconciliations from press releases [S2]
- Adversarial sweep results from web search across short-report and litigation sources [S3]
- Glencore reference / non-contagion analysis [S4]

#### Assumption Register Updates

| ID | Step | Assumption | Type | Value | Unit | Basis | Sensitivity | Source |
|----|------|-----------|------|-------|------|-------|-------------|--------|
| A17 | 04 | Use Adj EPS, not GAAP EPS, for forward valuation | Judgment | — | — | Street convention; structural wedge | High | A17 |
| A18 | 04 | Adversarial sweep clean — no active short reports, no SEC actions, no material litigation overhangs | Fact | — | — | Public-data sweep [S3] | Medium | A18 |
| A19 | 04 | Glencore's FCPA / regulatory history does not contagion-transfer to BG; treat as ownership-block governance variable not financial risk | Judgment | — | — | Legal isolation; no co-defendant filings | Low-Medium | A19 |
| A20 | 04 | Use multi-year OCF averages (5-year) for cash-quality assessment, not single-year snapshots | Judgment | — | — | Structural working-capital cycle | Medium | A20 |

#### Tables and Calculations

##### Earnings Quality Summary

| Metric | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | 5-yr Avg |
|--------|--------|--------|--------|--------|--------|---------|
| Revenue | 59,152 | 67,232 | 59,540 | 53,108 | 70,329 | 61,872 |
| GAAP NI ($M) | 2,078 | 1,610 | 2,243 | 1,137 | 816 | 1,577 |
| GAAP Diluted EPS | $13.64 | $10.51 | $14.87 | $7.99 | $4.91 | $10.38 |
| Adj EPS | n/d | n/d | n/d | $9.19 | $7.57 | $8.38 (2-yr) |
| OCF | -2,894 | -5,549 | 3,308 | 1,900 | 844 | -478 |
| OCF / NI (when positive) | n/a | n/a | 1.47x | 1.67x | 1.03x | 1.4x avg |
| Capex | 399 | 555 | 1,122 | 1,376 | 1,723 | 1,035 |
| FCF (OCF - Capex) | -3,293 | -6,104 | 2,186 | 524 | -879 | -1,513 |
| **FCF/NI multi-year average** | | | | | | mixed but normalizing |

##### Adversarial Sweep — Detailed Searches Run

| Search Query | Findings |
|--------------|----------|
| "Bunge BG short report" | None recent |
| "Bunge SEC investigation" | 2013 Argentina matter (resolved); none current |
| "Bunge class action lawsuit" | Routine commercial disputes; no material securities-fraud cases |
| "Bunge accounting fraud" | None |
| "Bunge FCPA bribery" | None against Bunge; Glencore separate |
| "Bunge deforestation Cerrado" | Reputation matter; not financial |
| "Bunge auditor change resignation" | None |

#### Open Questions and Data Gaps

- Auditor identity confirmation from latest 10-K
- 10-K's risk-factors detail (couldn't retrieve directly; relied on press summaries)
- Specific covenant details on Viterra-financing facility
- EUDR compliance certification confirmation

#### Next-Step Dependencies

- Step 05 will use the adjusted-vs-GAAP framework for quarterly KPI selection
- Step 06 will deepen the balance-sheet / leverage analysis
- Step 14 (in /complete-coverage) will use Adj EPS as the primary multiple input

#### Source Index

| Source Tag | Document or URL | Section / Page / Slide | Date | Notes |
|------------|----------------|----------------------|------|-------|
| [S1] | XBRL company facts summary | `BG_financials/xbrl/xbrl_summary.md` | 2026-05-28 | GAAP annual series |
| [S2] | Bunge Q4 2025 + Q1 2026 press releases | `BG_financials/presentations/investor_presentation_2026.md` + `BG_financials/other/stockanalysis_summary.md` | 2026-05-28 | Adj EPS, BS, cash flow |
| [S3] | Adversarial sweep — web search across short-report and litigation sources | Various (no specific URLs returned material findings) | 2026-05-28 | Clean |
| [S4] | Glencore reference & non-contagion analysis | Public-record review of Glencore FCPA settlements + Bunge co-defendant check | 2026-05-28 | No transfer |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BG/fundamental

## Navigation

- Overview: /stocks/BG
- Financials (this page): /stocks/BG/financials
- Thesis: /stocks/BG/thesis
- Investment Memo: /stocks/BG/memo
- Coverage universe: /stocks